Ebola Virus Disease Clinical Trial
Official title:
VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults
This study will determine if experimental vaccines to prevent Ebola virus infection and
Marburg virus infection are safe and what side effects, if any, they cause. Ebola virus
infection may range from mild to severe, and may cause breathing problems, severe bleeding,
kidney problems and shock that can lead to death. Marburg virus infection causes an illness
similar to that caused by the Ebola virus. The vaccines used in this study contain genetic
material produced in the laboratory that causes the body to make a small amount of either
Ebola or Marburg virus proteins. No Ebola or Marburg virus is in the vaccines.
Normal healthy volunteers between 18 and 60 years of age may be eligible for this study.
Participants are assigned to receive injections of either the Marburg or the Ebola vaccine.
The first group of participants will receive the Marburg vaccine and the second group will
receive the Ebola vaccine. The injections are given at 4-week intervals (study weeks 0, 4 and
8). They are given into a muscle with a needleless system called the Biojector(Registered
Trademark) 2000.
Participants keep a diary at home (on paper or electronically) for 5 days, in which they
record their temperature, symptoms and any reaction at the injection site. They call a study
nurse the day after vaccination to report how they feel and return to the clinic for
follow-up 2 weeks after each injection (weeks 2, 6 and 10). The visits include a check of
vital signs, blood and urine tests, medical history and review of medications taken.
Additional visits at weeks 12, 24 and 32 include a check of vital signs, medical history and
blood tests.
Study Design:
This is an open label Phase I study to evaluate safety, tolerability, and immunogenicity of
two recombinant DNA vaccines: one against Marburg virus infections and one against Ebola
virus infections. The hypothesis is that each vaccine will be safe for human administration
and elicit a humoral and T cell mediated immune response. The primary objectives are to
evaluate the safety and tolerability of the investigational vaccines in healthy adults.
Secondary and exploratory objectives are related to the immunogenicity of each study vaccine.
Product Description:
VRC-MARDNA025-00-VP (Marburg DNA) is composed of one closed-circular DNA plasmid encoding for
the glycoprotein (GP) from the Angola strain of Marburg. VRC-EBODNA023-00-VP (Ebola DNA WT)
is composed of two closed-circular DNA plasmids, one encodes for GP from the Zaire strain and
one encodes for GP from the Sudan-Gulu strain of Ebola. DNA vaccine vials will be supplied at
4 mg/mL. Each DNA vaccination will be 1 mL of vaccine administered intramuscularly (IM) into
the deltoid muscle using the Biojector[R] 2000 Needle-Free Injection Management System
(Biojector).
Subjects:
A total of 20 healthy adults, ages 18-60 years, will be enrolled into two groups of 10
subjects each. No more than one subject per group may be in the age range of 51-60 years.
Study Plan:
Subjects will be sequentially enrolled into two groups. Group 1 subjects will receive the
Marburg DNA vaccine and Group 2 subjects will receive the Ebola DNA WT vaccine. The first 3
enrollments in each group will occur no faster than one per day. Before completing enrollment
into each group, there will be a study pause with review by the Protocol Safety Review Team
(PSRT) when there is at least 2 weeks of safety follow-up on the third subject's first
injection. Before the initiation of Group 2, the FDA must have assessed administration of the
Ebola DNA WT vaccine as safe to proceed. In addition, there will be a study pause with review
by the PSRT when there is at least two weeks of safety follow-up on the last subject enrolled
into Group 1.
VRC 206 Group 1 will receive Marburg DNA, accrue 10 subjects and deliver injections on Day 0
with a dose 4 mg, Day 28 plus or minus 7 with a dose 4 mg and Day 56 plus or minus 7 with a
dose 4 mg.
VRC 206 Group 2 will receive Ebola DNA WT, accrue 10 subjects and deliver injections on Day 0
with a dose of 4 mg, Day 28 plus or minus 7 with a dose 4 mg and Day 56 plus or minus 7 with
a dose 4 mg.
The total accrual will be 20 subjects. The injections will be administered at least 21 days
between DNA injections.
The original protocol design required 9 clinic visits and 3 telephone follow-up contacts for
each subject.
The Version 4.0 protocol amendment allows a 4th injection for those who consent. Consent and
administration of the 4th injection could occur anytime in the interval starting with Study
Week 32 through Study Week 52. The 4th injection follow-up schedule includes 1 telephone
contact and 4 follow-up visits after the injection.
Study Duration: The original study requires 32 weeks of clinical follow up for each
participant. Subjects who consent to the amended schedule with a 4th injection will have an
additional 12 weeks of follow up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00374309 -
Experimental Vaccine for Prevention of Ebola Virus Infection
|
Phase 1 | |
Completed |
NCT03098862 -
PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
|
||
Completed |
NCT02509494 -
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
|
Phase 3 | |
Recruiting |
NCT06093646 -
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
|
N/A | |
Completed |
NCT02495246 -
A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV
|
Phase 1 | |
Completed |
NCT04906629 -
INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees
|
Phase 1 | |
Completed |
NCT05064956 -
Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)
|
Phase 2 | |
Not yet recruiting |
NCT06126822 -
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
|
Phase 3 | |
Completed |
NCT02267109 -
Phase 1 Trial of Ebola Vaccine in Mali
|
Phase 1 | |
Withdrawn |
NCT04268966 -
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
|
Phase 2 | |
Not yet recruiting |
NCT04822376 -
Prophylaxis Vaccine Antibodies Ebola
|
Phase 2 | |
Recruiting |
NCT02333578 -
Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
|
N/A | |
Completed |
NCT02662855 -
Efficacy of Favipiravir Against Severe Ebola Virus Disease
|
Phase 2 | |
Active, not recruiting |
NCT04152486 -
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
|
Phase 3 | |
Terminated |
NCT04250168 -
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
|
||
Completed |
NCT03161366 -
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
|
Phase 3 | |
Completed |
NCT03140774 -
Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
|
||
Suspended |
NCT03462004 -
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
|
Phase 1 | |
Active, not recruiting |
NCT02876328 -
Partnership for Research on Ebola VACcinations
|
Phase 2 | |
Not yet recruiting |
NCT05202288 -
Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
|
Phase 2 |